Johnson & Johnson's US orthopedic sales dip 4.5% in Q3: 5 notes

Carly Behm -   Print  |
  • Small
  • Medium
  • Large

Johnson & Johnson reported a 4.5 percent decrease in orthopedic sales in the third quarter, but global sales saw a slight increase, according to financial results posted Oct. 19.

Five notes:

1. In the U.S., orthopedic medical device sales were $1.2 billion in the third quarter compared to $1.3 billion in the same period last year. Globally, orthopedic sales were $2 billion, a 0.5 percent increase year over year.

2. Hip and knee sales saw decreases in the U.S. Hip sales were $210 million, down 5.3 percent year over year. Knee sales were $184 million, a decrease of 9.8 percent compared to the third quarter last year.

3. Globally, hip and knee sales saw slight upticks in sales. Worldwide hip and knee sales were up 3.3 percent and 2.8 percent, respectively, compared to the same time last year.

4. Spine sales dipped in the U.S. and globally. In the U.S., spine, sports and other medical device sales were $400 million, down 11.1 percent year over year. Globally, sales in that segment fell 5.3 percent from the same period last year. 

5. Johnson & Johnson's whole medical device business saw an 8 percent increase in revenue with $6.6 billion in sales, compared to $6.1 billion in the same period last year.

Copyright © 2021 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

Featured Webinars

Featured Whitepapers

Featured Podcast